TCL1 (MRQ-7) Mouse Monoclonal Antibody
SIGMA/357M-1
Product Type: Chemical
Immunohistochemistry TCL1 (MRQ-7) on Burkitt′s lymphoma
| antibody form | culture supernatant |
| antibody product type | primary antibodies |
| biological source | mouse |
| clone | MRQ-7, monoclonal |
| conjugate | unconjugated |
| control | B-cell lymphoma, tonsil |
| description | For In Vitro Diagnostic Use in Select Regions (See Chart) |
| form | buffered aqueous solution |
| isotype | IgG |
| manufacturer/tradename | Cell Marque® |
| packaging | bottle of 1.0 mL predilute (357M-17) |
| bottle of 7.0 mL predilute (357M-18) | |
| vial of 0.1 mL concentrate (357M-14) | |
| vial of 0.5 mL concentrate (357M-15) | |
| vial of 1.0 mL concentrate (357M-16) | |
| Quality Level | 100  |
| 500 |
|
| shipped in | wet ice |
| species reactivity | human |
| storage temp. | 2-8°C |
| technique(s) | immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500 |
| visualization | cytoplasmic, nuclear |
| Analysis Note: |
|
||||
| General description: | T-cell leukemia/lymphoma protein 1 (TCL1, TCL1A, p14TCL1) is a 14 kDa product of the TCL1 gene that is involved in T-cell prolymphocytic leukemia (T-PLL). TCL1 protein is normally found in the nucleus and cytoplasm of lymphoid lineage cells during early embryogenesis. Chromosomal translocations may lead to overexpression of TCL1, resulting in T-cell leukemia and B-cell lymphoma. TCL1 binds to a novel site in the pleckstrin homology (PH) domain, resulting in activation and nuclear translocation of Akt by overexpressed TCL1 which may promote an anti-apoptotic response; this may normally serve to promote growth during development but may lead to malignancy when TCL1 is overexpressed. TCL1 is expressed in differentiated B-cells under both reactive and neoplastic conditions, antigen committed B-cells, and in germinal center B-cells. TCL1 is down-regulated in the latest stage of B-cell differentiation. TCL1 is overexpressed in Burkitt lymphoma, the majority of AIDS-related non-Hodgkin lymphoma-designated immunoblastic plasmacytoid lymphoma, lymphoblastic lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, and primary cutaneous B-cell lymphoma. Therefore, the most useful application of anti-TCL1 is the discrimination of B-cell lymphomas from T-cell lymphomas, CD30+ anaplastic large cell lymphomas, multiple myeloma, and marginal zone B-cell lymphoma. | ||||
| Legal Information: | Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany | ||||
| Other Notes: | For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com | ||||
| Other Notes: | TCL1 Positive Control Slides, Product No. 357S , are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections). |
||||
| Physical form: | Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide | ||||
| Preparation Note: | Download the IFU specific to your product lot and format  Note: This requires a keycode which can be found on your packaging or product label. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 2 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352203 |